Shelley M et al., 2006-10-18: Cochrane review of chemotherapy for hormone-refractory (castration-resistant) prostate cancer. It concludes docetaxel-based regimens improved survival, symptom palliation and quality of life, and that chemotherapy should be considered a treatment option.
Recent data from randomised studies, in particular those using docetaxel, have provided encouraging improvements in overall survival, palliation of symptoms, and improvements in quality of life.
Abstract (AUTHORS' CONCLUSIONS)
Shelley M et al., 2006-10-18: Cochrane review of chemotherapy for hormone-refractory (castration-resistant) prostate cancer. It concludes docetaxel-based regimens improved survival, symptom palliation and quality of life, and that chemotherapy should be considered a treatment option. Funder: not recoverable from the record captured (PMC full text unavailable at retrieval; abstract carries no funding statement). Declarations: 'None'. Drug: docetaxel and other cytotoxics; makers not named. Comparator: prednisone/mitoxantrone and best supportive care in the trials reviewed. This is the 2006 edition; no later Cochrane review of chemotherapy in castration-resistant disease was located. PMC12399875. Study type: review.
